Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. The Company’s lead drug candidate, REMOXY, is an extended-release oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. REMOXY is a controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes excipients. REMOXY’s capsule dosage form provides therapeutic drug levels of oxycodone on a twice-daily dosing schedule, while resisting the increases in plasma levels of oxycodone associated with certain common methods of abuse and misuse. The Company’s drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational New Drug-stage of development.